Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer
In recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC), survival outcomes are significantly better in patients who receive anti-programmed cell death-1 (PD-1) monoclonal antibody therapy than in those who receive standard therapy. However, there is no established biomarker that...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/6/410 |
| _version_ | 1797595360393166848 |
|---|---|
| author | Katsunori Tanaka Hitoshi Hirakawa Mikio Suzuki Teruyuki Higa Shinya Agena Narumi Hasegawa Junko Kawakami Masatomo Toyama Tomoyo Higa Hidetoshi Kinjyo Norimoto Kise Shunsuke Kondo Hiroyuki Maeda Taro Ikegami |
| author_facet | Katsunori Tanaka Hitoshi Hirakawa Mikio Suzuki Teruyuki Higa Shinya Agena Narumi Hasegawa Junko Kawakami Masatomo Toyama Tomoyo Higa Hidetoshi Kinjyo Norimoto Kise Shunsuke Kondo Hiroyuki Maeda Taro Ikegami |
| author_sort | Katsunori Tanaka |
| collection | DOAJ |
| description | In recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC), survival outcomes are significantly better in patients who receive anti-programmed cell death-1 (PD-1) monoclonal antibody therapy than in those who receive standard therapy. However, there is no established biomarker that can predict the anti-PD-1 antibody treatment effect and immune-related adverse events (irAEs) in these patients. This study investigated the inflammatory and nutritional status in 42 patients with R/M-HNSCC and programmed cell death ligand-1 (PD-L1) polymorphisms (rs4143815 and rs2282055) in 35 of the 42 patients. The 1- and 2-year overall survival was 59.5% and 28.6%, respectively; the 1- and 2-year first progression-free survival was 19.0% and 9.5%, respectively, and the respective second progression-free survival was 50% and 27.8%. Performance status and inflammatory and nutritional status (assessed by the geriatric nutritional risk index, modified Glasgow prognostic score, and prognostic nutritional index) were identified as significant indicators of survival outcomes in multivariate analysis. Patients with ancestral alleles in PD-L1 polymorphisms had less frequent irAEs. Performance status and inflammatory and nutritional status before treatment were closely related to survival outcomes after PD-1 therapy. These indicators can be calculated using routine laboratory data. PD-L1 polymorphisms may be biomarkers for predicting irAEs in patients receiving anti-PD-1 therapy. |
| first_indexed | 2024-03-11T02:36:18Z |
| format | Article |
| id | doaj.art-ea2dbcb674574ff8bd6cac5d6b339b0d |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-11T02:36:18Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-ea2dbcb674574ff8bd6cac5d6b339b0d2023-11-18T09:57:47ZengMDPI AGCurrent Oncology1198-00521718-77292023-06-013065409542410.3390/curroncol30060410Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck CancerKatsunori Tanaka0Hitoshi Hirakawa1Mikio Suzuki2Teruyuki Higa3Shinya Agena4Narumi Hasegawa5Junko Kawakami6Masatomo Toyama7Tomoyo Higa8Hidetoshi Kinjyo9Norimoto Kise10Shunsuke Kondo11Hiroyuki Maeda12Taro Ikegami13Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, JapanIn recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC), survival outcomes are significantly better in patients who receive anti-programmed cell death-1 (PD-1) monoclonal antibody therapy than in those who receive standard therapy. However, there is no established biomarker that can predict the anti-PD-1 antibody treatment effect and immune-related adverse events (irAEs) in these patients. This study investigated the inflammatory and nutritional status in 42 patients with R/M-HNSCC and programmed cell death ligand-1 (PD-L1) polymorphisms (rs4143815 and rs2282055) in 35 of the 42 patients. The 1- and 2-year overall survival was 59.5% and 28.6%, respectively; the 1- and 2-year first progression-free survival was 19.0% and 9.5%, respectively, and the respective second progression-free survival was 50% and 27.8%. Performance status and inflammatory and nutritional status (assessed by the geriatric nutritional risk index, modified Glasgow prognostic score, and prognostic nutritional index) were identified as significant indicators of survival outcomes in multivariate analysis. Patients with ancestral alleles in PD-L1 polymorphisms had less frequent irAEs. Performance status and inflammatory and nutritional status before treatment were closely related to survival outcomes after PD-1 therapy. These indicators can be calculated using routine laboratory data. PD-L1 polymorphisms may be biomarkers for predicting irAEs in patients receiving anti-PD-1 therapy.https://www.mdpi.com/1718-7729/30/6/410anti-programmed cell death-1 antibodyprogrammed cell death ligand-1polymorphismnutritionhead and neck cancerimmune-related adverse events |
| spellingShingle | Katsunori Tanaka Hitoshi Hirakawa Mikio Suzuki Teruyuki Higa Shinya Agena Narumi Hasegawa Junko Kawakami Masatomo Toyama Tomoyo Higa Hidetoshi Kinjyo Norimoto Kise Shunsuke Kondo Hiroyuki Maeda Taro Ikegami Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer Current Oncology anti-programmed cell death-1 antibody programmed cell death ligand-1 polymorphism nutrition head and neck cancer immune-related adverse events |
| title | Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer |
| title_full | Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer |
| title_fullStr | Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer |
| title_full_unstemmed | Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer |
| title_short | Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer |
| title_sort | biomarkers for predicting anti programmed cell death 1 antibody treatment effects in head and neck cancer |
| topic | anti-programmed cell death-1 antibody programmed cell death ligand-1 polymorphism nutrition head and neck cancer immune-related adverse events |
| url | https://www.mdpi.com/1718-7729/30/6/410 |
| work_keys_str_mv | AT katsunoritanaka biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT hitoshihirakawa biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT mikiosuzuki biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT teruyukihiga biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT shinyaagena biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT narumihasegawa biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT junkokawakami biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT masatomotoyama biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT tomoyohiga biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT hidetoshikinjyo biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT norimotokise biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT shunsukekondo biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT hiroyukimaeda biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer AT taroikegami biomarkersforpredictingantiprogrammedcelldeath1antibodytreatmenteffectsinheadandneckcancer |